Product Description
Bellus Health is developing Camlipixant as a treatment for refractory chronic cough. (Sourced from: https://bellushealth.com/pipeline)
Mechanisms of Action: P2X3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Canada, China, Colombia, Czech Republic, France, Germany, Hungary, India, Israel, Japan, Korea, Netherlands, New Zealand, Poland, Slovakia, South Africa, South Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Refractory Chronic Cough|Signs and Symptoms, Respiratory|Unexplained Chronic Cough
Phase 2: Irritable Bowel Syndrome
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05600777 |
CALM-2 | P3 |
Active, not recruiting |
Refractory Chronic Cough|Signs and Symptoms, Respiratory|Unexplained Chronic Cough |
2026-06-11 |
8% |
2026-04-16 |
Primary Endpoints |
NCT07519395 |
BALANCE | P2 |
Not yet recruiting |
Irritable Bowel Syndrome |
2027-03-05 |
12% |
2026-04-10 |
Primary Endpoints|Treatments |
NCT05570539 |
BUS-P1-09 | P1 |
Completed |
Healthy Volunteers |
2024-05-02 |
50% |
2025-05-20 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments |
2022-000188-38 |
CALM-2 | P3 |
Active, not recruiting |
Unexplained Chronic Cough|Refractory Chronic Cough |
2026-08-08 |
|||
jRCT2031230611 |
jRCT2031230611 | P3 |
Not yet recruiting |
Refractory Chronic Cough|Unexplained Chronic Cough |
2026-06-30 |
|||
2024-513460-26-00 |
BUS-P3-01 | P3 |
Active, not recruiting |
Unexplained Chronic Cough|Refractory Chronic Cough |
2026-05-11 |
2025-05-02 |
Treatments |
|
2024-513462-19-00 |
BUS-P3-02 | P3 |
Recruiting |
Unexplained Chronic Cough|Refractory Chronic Cough |
2026-03-27 |
8% |
2025-05-02 |
Treatments |
NCT06222892 |
NCT06222892 | P1 |
Completed |
Healthy Volunteers |
2024-12-17 |
50% |
2026-01-08 |
Primary Endpoints|Treatments |
NCT05599191 |
CALM-1 | P3 |
Active, not recruiting |
Unexplained Chronic Cough|Refractory Chronic Cough |
2025-12-18 |
2025-06-11 |
Primary Endpoints |
|
NCT06497517 |
NCT06497517 | P1 |
Completed |
Healthy Volunteers |
2024-08-22 |
50% |
2025-02-08 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |